P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials
Devika Aggarwal(Beaumont Hospital, Royal Oak), Arman Qamar(NorthShore University HealthSystem), Thomas A. Zelniker(Medical University of Vienna), Cheong Lee(NorthShore University HealthSystem), Eliano Pio Navarese(Nicolaus Copernicus University), Justin Levisay(NorthShore University HealthSystem), Vardhmaan Jain(Cleveland Clinic), Gregory Mishkel(NorthShore University HealthSystem), Sameer Arora(University of North Carolina at Chapel Hill), Zainali Chunawala(Southwestern Medical Center), Sripal Bangalore(New York University), Mark J. Ricciardi(NorthShore University HealthSystem), Kirtipal Bhatia(Mount Sinai Hospital), Simon Dixon(Beaumont Hospital, Royal Oak), Debabrata Mukherjee(Texas Tech University), Remo H M Furtado(Hospital Israelita Albert Einstein), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 39
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
A Controlled Trial of Renal Denervation for Resistant Hypertension
|New England Journal of Medicine|2014|2.2k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k